Status:
COMPLETED
Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application
Lead Sponsor:
Dong-A ST Co., Ltd.
Conditions:
Androgenetic Alopecia
Eligibility:
MALE
18-49 years
Phase:
PHASE1
PHASE2
Brief Summary
This study is designed to explore the efficacy and safety of DA-4001 after topical application in male patients with androgenetic alopecia Design : Randomized, double-blind, active-controlled study ...
Eligibility Criteria
Inclusion
- Basic and specific(BASP) classification : basic type is M2 or C2 and specific type is V1,V2 or F1,F2
Exclusion
- Evidence of hair loss other than androgenetic alopecia
- Use of finasteride, dutasteride within previous 12 months
- Use of minoxidil within previous 6 months
- Use of androgenic or anti-androgenic agents within previous 6 months
- Use of steroid agents for local application to scalp or systemic application within previous 1 month
- History of hair transplantation, scalp reduction
- Coronary artery disease, arrhythmia, congestive heart failure, valvular haert disease, angina pectoris
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT02280603
Start Date
January 1 2014
End Date
December 1 2014
Last Update
June 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Catholic Medical Center
Seoul, Dongdaemun-gu, South Korea, 130-709